Isolated Progressive Cardiac Conduction Disease

ByL. Brent Mitchell, MD, Libin Cardiovascular Institute of Alberta, University of Calgary
Reviewed/Revised Jun 2024
View Patient Education

Isolated progressive cardiac conduction disease (PCCD) refers to a group of genetic disorders that involve progressively worsening defects in cardiac conduction, including sinus node dysfunction, varying degrees of atrioventricular (AV) block and/or His-Purkinje system conduction delays or blocks.

    PCCD may be

    • Structural: Accompanied or followed by structural heart disease (eg, congenital heart disease, cardiomyopathy)

    • Isolated: Occurring in a structurally normal heart

    The most common form of PCCD associated with a cardiomyopathy is one in which mutations in LMNA are present (see Lamin A/C Cardiomyopathies). Some such patients present with an apparently structurally normal heart but subsequently develop cardiomyopathy.

    Patients with isolated PCCD typically present with early-onset (age < 50 years) progressive conduction system disease, which manifests as one or more of the following:

    A degenerative form, in which the conducting system becomes sclerotic, has been referred to as Lenègre-Lev disease

    Isolated PCCD results predominantly from mutations in SCN5A, the gene that encodes the Nav1.5 channel responsible for the inward sodium (INa) current. Inheritance is typically in an autosomal dominant pattern. Overlap syndromes with the long QT syndrome and with Brugada syndrome have been reported (1).

    The disorder is manifest by ECG changes including prolonged PR interval, widened P wave, widened QRS complex, AV block, right bundle branch block, left anterior hemiblock, left posterior hemiblock, left bundle branch block, or nonspecific interventricular conduction block. Patients also have a higher risk of sudden death.

    Patients should have cardiac imaging (eg, echocardiography, MRI) to detect any structural disorders. Patients without structural disease should have genetic testing, particularly if they have a family history of sudden cardiac death or of need for pacemaker implantation at a young age. If testing reveals a genetic abnormality, family members should be screened with ECG and genetic testing.

    Treatment is with a pacemaker following the usual indications for pacemaker implantation, including third-degree AV block or symptomatic second-degree AV block. Because PCCD is progressive, there is a consensus recommendation that pacemakers may also be useful in patients with isolated PCCD who have bifasicular block (2).

    References

    1. 1.  Asatryan B, Medeiros-Domingo A: Molecular and genetic insights into progressive cardiac conduction disease. Europace 21(8):1145–1158, 2019. doi: 10.1093/europace/euz109

    2. 2. Priori SG, Wilde AA, Horie M, et al: HRS/EHRA/APHRS Expert Consensus Statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 10:1932–1963, 2013. doi: 10.1016/j.hrthm.2013.05.014

    quizzes_lightbulb_red
    Test your KnowledgeTake a Quiz!
    Download the free Merck Manual App iOS ANDROID
    Download the free Merck Manual App iOS ANDROID
    Download the free Merck Manual App iOS ANDROID